Hangzhou Sciwind Biosciences Co Ltd, a clinical-stage biotech company focusing on research and development of innovative biologics, announced on Sunday that it has received approval for the clinical trial of company's XW003, a potential candidate for the treatment of non-alcoholic steatohepatitis (NASH) from China's regulator, NMPA.

Two additional clinical trial applications with the product were earlier approved for the treatment of type 2 diabetes mellitus and overweight/obesity in 2020.

The company is to start a series of phase two trials including multiple metabolic indications, including diabetes, obesity and NASH etc.